ClinicalTrials.gg
CompletedNCT04434937Updated Oct 23, 2024Results posted

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

A Phase 2 interventional study of parsaclisib in Lymphoma, sponsored by Incyte Biosciences Japan GK. Completed at 30 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.

Primary conditionLymphoma, FollicularRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Follicular
Why
  1. The study's title name Lymphoma, Follicular, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Incyte Biosciences Japan GK (part of Incyte Corporation) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Lymphoma, Follicular with a site in Japan — 8 open to participants now, 25 under way, 9 of them phase 3. Lymphoma, Follicular · Japan.

Enrollment
47th of 57
42 · median 231
Started
2020
with 4 others
Phase 2
12 of 59
1 open now
Registered
34th of 59
by date

Among the 59 studies in Lymphoma, Follicular with a site in Japan, this one is the 47th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2020, is one of 12 in phase 2, and was the 34th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 59 studies in Lymphoma, Follicular with a site in Japan are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Lymphoma, Follicular with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma

03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • Follicular Lymphoma
  • Parsaclisib
  • PI3Kδ Inhibitor
04

In context

Lymphoma, Follicular Reclassified

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

This study's enrollment of 42 is below the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Incyte Biosciences Japan GK is the lead sponsor of 6 studies on the registry; none are open to participants now.

Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Japanese participant who must be ≥ 18 years of age
  • Ability to comprehend and willingness to sign a written ICF and comply with all study visits and procedures
  • confirmed, , FL Grade 1, 2, and 3a
  • Ineligible for
  • Must have been treated with at least 2 prior systemic therapies for FL
  • Radiographically measurable lymphadenopathy or extranodal lymphoid (defined as the presence of ≥ 1 lesion that measures > 1.5 cm in the LD and ≥ 1.0 cm in the LPD, respectively) as assessed by CT or MRI
  • Participants must be willing to undergo an incisional, excisional, or core needle lymph node or tissue or provide a lymph node or tissue biopsy collected after the completion of last therapy. An earlier archived lymph node or tissue biopsy is acceptable if hospitalization is required for biopsy (eg. no superficial lymph node) and SUVmax by FDG-PET is \< 14
  • performance status 0 to 2
  • ≥ 12 weeks
  • Adequate hematologic, hepatic, and renal functions ≥ 1.0 × 109/L ≥ 8.0 g/dL. count ≥ 50 × 109/L. Total ≤ 1.5 × . Participants with documented history of Gilbert's syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible.

/AST ≤ 2.5× ULN or ≤ 5 × ULN in the presence of liver involvement. Calculated ≥ 40 mL/min by the Cockcroft-Gault Equation or the estimated ≥ 40 mL/min/1.73 m2 using the Modification of Diet in Renal Disease formula.

  • Female participants agree to use medically acceptable measures, should not be breastfeeding, and must have a negative pregnancy test before the start of study drug administration.
  • Female participants of must understand and accept that pregnancy must be avoided during participation in the study.
  • Male participants should avoid fathering children from screening through at least 93 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Known histological transformation from indolent NHL to DLBCL
  • History of central nervous system lymphoma (either primary or )
  • Prior treatment with the following:

    1. Selective PI3Kδ or pan-PI3K inhibitors (eg, idelalisib, copanlisib, duvelisib, etc).
    2. Bruton's tyrosine kinase inhibitor (eg, ibrutinib).
  • SCT within the last 6 months, or autologous SCT within the last 3 months before the date of study treatment administration
  • Active
  • Use of therapy within 28 days of the date of study treatment administration
  • Concurrent anticancer therapy
  • Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease
  • Current or previous other within 3 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.
  • (HBV) or infection
  • Current Class II to IV congestive heart failure or uncontrolled arrhythmia
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    parsaclisib

    parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits

    Drug: parsaclisib

Interventions

  • parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits

    Also known as: INCB050465

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) as defined by revised response criteria for lymphoma, as determined by an Independent Review Committee (IRC). CR: target nodes/nodal masses regressed to ≤1.5 centimeters (cm) in the longest transverse diameter (LDi); no nonmeasured lesions; regression to normal for organ enlargement; no new lesions; and normal bone marrow by morphology and negative immunohistochemistry if indeterminate. PR: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites; absent/regressed nonmeasured lesions (but no increase); spleen regressed by \>50% in length beyond normal; and no new lesions.

    Time frame: up to approximately 3 years

Secondary outcomes

  1. Complete Response Rate (CRR)

    CRR was defined as the percentage of participants with a CR as defined by revised response criteria for lymphoma, as determined by an IRC. CR was defined as: target nodes/nodal masses regressed to ≤1.5 cm in the LDi; no nonmeasured lesions; regression to normal for organ enlargement; no new lesions; and normal bone marrow by morphology and negative immunohistochemistry if indeterminate.

    Time frame: up to approximately 3 years

  2. Duration of Response (DOR)

    DOR was defined as the time from the first documented evidence of CR or PR until disease progression or death from any cause among participants who achieved an objective response, as determined by radiographic disease assessment provided by an IRC. Progressive disease was defined as ≥1 of the following: abnormal individual node/lesion meeting specific criteria; new/recurrent splenomegaly; new/clear progression of pre-existing nonmeasured lesions; regrowth of any previously resolved lesions; new node \>1.5 cm in any axis; new extranodal site \>1.0 cm in any axis; assessable disease of any size attributable to lymphoma; new/recurrent involvement of bone marrow.

    Time frame: up to 20.0 months

  3. Progression-free Survival (PFS)

    PFS was defined as the time from the date of the first dose of study treatment until the earliest date of disease progression, as determined by radiographic disease assessment provided by an IRC, or death from any cause. Progressive disease was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

    Time frame: up to approximately 3 years

  4. Overall Survival

    Overall survival was defined as the time from the date of the first dose of study treatment until death from any cause.

    Time frame: up to approximately 3 years

  5. Best Percentage Change in Target Lesion Size From Baseline, as Determined by Independent Review Committee and the Investigator

    Target lesion size was measured by the sum of the products of the diameters of all target lesion sizes. The best percent change from Baseline was defined as the largest decrease, or smallest increase if no decrease, from Baseline in target lesion sizes on/before new anti-lymphoma therapy during the study. Percentage change was calculated as (\[the post-Baseline value minus the Baseline value\] / the Baseline value) x 100.

    Time frame: up to approximately 3 years

  6. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last administration of study drug.

    Time frame: up to 1041 days

  7. Number of Participants With Any Grade 3 or Higher TEAE

    An adverse event was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last administration of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 1041 days

08

Results

Posted Jan 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneParsaclisib 20 mg/2.5 mg
Started42
Completed0
Not completed42
Withdrew: Death4
Withdrew: Withdrawal by subject1
Withdrew: Transitioned to rollover study19
Withdrew: Progressive disease18

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) as defined by revised response criteria for lymphoma, as determined by an Independent Review Committee (IRC). CR: target nodes/nodal masses regressed to ≤1.5 centimeters (cm) in the longest transverse diameter (LDi); no nonmeasured lesions; regression to normal for organ enlargement; no new lesions; and normal bone marrow by morphology and negative immunohistochemistry if indeterminate. PR: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites; absent/regressed nonmeasured lesions (but no increase); spleen regressed by \>50% in length beyond normal; and no new lesions.

Time frame:
up to approximately 3 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsParsaclisib 20 mg/2.5 mg
Objective Response Rate (ORR)88.1 (74.4 to 96.0)
SecondaryComplete Response Rate (CRR)

CRR was defined as the percentage of participants with a CR as defined by revised response criteria for lymphoma, as determined by an IRC. CR was defined as: target nodes/nodal masses regressed to ≤1.5 cm in the LDi; no nonmeasured lesions; regression to normal for organ enlargement; no new lesions; and normal bone marrow by morphology and negative immunohistochemistry if indeterminate.

Time frame:
up to approximately 3 years
Reported as:
Number · percentage of participants
Complete Response Rate (CRR)
percentage of participantsParsaclisib 20 mg/2.5 mg
Complete Response Rate (CRR)23.8 (12.1 to 39.5)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first documented evidence of CR or PR until disease progression or death from any cause among participants who achieved an objective response, as determined by radiographic disease assessment provided by an IRC. Progressive disease was defined as ≥1 of the following: abnormal individual node/lesion meeting specific criteria; new/recurrent splenomegaly; new/clear progression of pre-existing nonmeasured lesions; regrowth of any previously resolved lesions; new node \>1.5 cm in any axis; new extranodal site \>1.0 cm in any axis; assessable disease of any size attributable to lymphoma; new/recurrent involvement of bone marrow.

Time frame:
up to 20.0 months
Reported as:
Median · months
Duration of Response (DOR)
monthsParsaclisib 20 mg/2.5 mg
Duration of Response (DOR)NA (8.02 to NA)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the date of the first dose of study treatment until the earliest date of disease progression, as determined by radiographic disease assessment provided by an IRC, or death from any cause. Progressive disease was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Time frame:
up to approximately 3 years
Reported as:
Median · months
Progression-free Survival (PFS)
monthsParsaclisib 20 mg/2.5 mg
Progression-free Survival (PFS)NA (11.17 to NA)
SecondaryOverall Survival

Overall survival was defined as the time from the date of the first dose of study treatment until death from any cause.

Time frame:
up to approximately 3 years
Reported as:
Median · months
Overall Survival
monthsParsaclisib 20 mg/2.5 mg
Overall SurvivalNA (23.06 to NA)
SecondaryBest Percentage Change in Target Lesion Size From Baseline, as Determined by Independent Review Committee and the Investigator

Target lesion size was measured by the sum of the products of the diameters of all target lesion sizes. The best percent change from Baseline was defined as the largest decrease, or smallest increase if no decrease, from Baseline in target lesion sizes on/before new anti-lymphoma therapy during the study. Percentage change was calculated as (\[the post-Baseline value minus the Baseline value\] / the Baseline value) x 100.

Time frame:
up to approximately 3 years
Reported as:
Mean · percent change
Best Percentage Change in Target Lesion Size From Baseline, as Determined by Independent Review Committee and the Investigator
percent changeParsaclisib 20 mg/2.5 mg
Independent Review Committee-67.26 ± 39.897
Investigator-79.31 ± 23.181
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last administration of study drug.

Time frame:
up to 1041 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsParsaclisib 20 mg/2.5 mg
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)42
SecondaryNumber of Participants With Any Grade 3 or Higher TEAE

An adverse event was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last administration of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 1041 days
Reported as:
Count of participants · Participants
Number of Participants With Any Grade 3 or Higher TEAE
ParticipantsParsaclisib 20 mg/2.5 mg
Number of Participants With Any Grade 3 or Higher TEAE28

Adverse events

Collected over up to 1041 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Parsaclisib 20 mg/2.5 mg4/42 (9.5%)15/42 (35.7%)38/42 (90.5%)
Total4/42 (9.5%)15/42 (35.7%)38/42 (90.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventParsaclisib 20 mg/2.5 mgTotal
StomatitisGastrointestinal disorders3/423/42
COVID-19Infections and infestations2/422/42
Cardiac failureCardiac disorders2/422/42
Cytomegalovirus colitisInfections and infestations2/422/42
Aortic aneurysmVascular disorders1/421/42
ArthritisMusculoskeletal and connective tissue disorders1/421/42
Atrial fibrillationCardiac disorders1/421/42
CataractEye disorders1/421/42
CheilitisGastrointestinal disorders1/421/42
Cytomegalovirus enteritisInfections and infestations1/421/42
Most frequent other events
Showing 10 of 24
Most frequent other events
EventParsaclisib 20 mg/2.5 mgTotal
DiarrhoeaGastrointestinal disorders11/4211/42
Neutrophil count decreasedInvestigations9/429/42
ConstipationGastrointestinal disorders8/428/42
StomatitisGastrointestinal disorders8/428/42
Cytomegalovirus infection reactivationInfections and infestations6/426/42
ArthralgiaMusculoskeletal and connective tissue disorders5/425/42
EczemaSkin and subcutaneous tissue disorders5/425/42
Herpes zosterInfections and infestations5/425/42
NeutropeniaBlood and lymphatic system disorders5/425/42
PruritusSkin and subcutaneous tissue disorders5/425/42

Baseline characteristics

Age, Continuous
Age, Continuous(years)Parsaclisib 20 mg/2.5 mg
Mean67.5 ± 7.81
Sex: Female, Male
Sex: Female, Male(Participants)Parsaclisib 20 mg/2.5 mg
Female20
Male22
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Parsaclisib 20 mg/2.5 mg
American Indian or Alaska Native0
Asian42
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Target lesion size, as determined by Independent Review Committee and the Investigator
Target lesion size, as determined by Independent Review Committee and the Investigator(millimeters squared (mm^2))Parsaclisib 20 mg/2.5 mg
Independent Review Committee2210.12 ± 1456.044
Investigator2487.24 ± 2197.143
09

Study locations

30 sites
  • Ja-Aichi Anjo Kosei Hospital
    Anjo, 446-8602, Japan
  • University of Fukui Hospital
    Fukui, 910-1193, Japan
  • Jcho Kyushu Hospital
    Fukuoka, 806-8501, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
  • Kansai Medical University Hospital
    Hirakata, 573-1191, Japan
  • Hokuyukai Sapporo Hokuyu Hospital
    Hokkaido, 003-0006, Japan
  • Hyogo College of Medicine Hospital
    Hyogo, 663-8501, Japan
  • Nho Mito Medical Center
    Ibaraki, 311-3193, Japan
  • Tokai University Hospital
    Isehara, 259-1193, Japan
  • Jiaikai Imamura General Hospital
    Kagoshima, 890-0064, Japan
  • Kobe City Medical Center General Hospital
    Kobe, 650-0047, Japan
  • University Hospital Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • Nho Matsumoto Medical Center
    Matsumoto, 399-8701, Japan
  • Nho Shikoku Cancer Center
    Matsuyama, 791-0280, Japan
  • Nagano Red Cross Hospital
    Nagano, 380-8582, Japan
  • National Hospital Organization Nagoya Medical Center
    Nagoya, 460-0001, Japan
  • Japanese Red Cross Nagoya Daini Hospital
    Nagoya, 466-8650, Japan
  • Red Cross Nagoya Daini Hospital
    Nagoya, 4668650, Japan
  • Tenri Hospital
    Nara, 632-8552, Japan
  • Miyagi Cancer Center
    Natori, 981-1293, Japan
  • Niigata Cancer Center Hospital
    Niigata, 951-8566, Japan
  • Ogaki Municipal Hospital
    Ogaki, 5038502, Japan
  • Okayama University Hospital
    Okayama, 700-8558, Japan
  • Nho Hokkaido Cancer Center
    Sapporo, 003-0804, Japan
  • Tohoku University Hospital
    Sendai-shi, 980-8574, Japan
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • Nippon Medical School Hospital
    Tokyo, 113-8603, Japan
  • Yokohama Municipal Citizens Hospital
    Yokohama, 221-0855, Japan
  • Yokohama City University Medical Center
    Yokohama, 232-0024, Japan
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Feb 2023, 28 months.

Results were first posted in Jan 2024, 10 months after primary completion.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 28 months is close to that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 17, 2020
StartActual
Sep 30, 2020
Primary completionActual
Feb 16, 2023
CompletionActual
Oct 13, 2023
Results first posted
Jan 3, 2024
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04434937
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Sep 30, 2020
Primary completion
Feb 16, 2023
Completion
Oct 13, 2023
Results posted
Jan 3, 2024
Last update
Oct 23, 2024

Study contacts

Incyte Medical Monitor
study director · Incyte Biosciences Japan GK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Parsaclisib

Start the discussion